Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France

Launched by NOVARTIS PHARMACEUTICALS · Nov 27, 2023

Keywords

ClinConnect Summary

The SEPROS trial is studying how the treatment of multiple sclerosis (MS) with a medication called ofatumumab affects the quality of life for patients in real-life situations in France. This study is not a clinical trial where participants are assigned to a specific treatment; instead, it observes patients who are starting ofatumumab treatment based on their doctor's recommendation. The goal is to gather information on how patients feel and function while receiving this medication.

To be eligible for the study, participants need to be at least 18 years old and have a confirmed diagnosis of MS. They should be starting ofatumumab treatment for the first time and must agree to take part in the study by completing some questionnaires. The study is currently recruiting participants, and it welcomes people of all genders. If you're considering joining, you can expect to share your experiences and provide feedback on your health and well-being during your treatment journey.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female, 18 years of age or older
• • 2. Patient with confirmed MS diagnosis
• • 3. Patient initiating treatment with ofatumumab for the first time
• • 4. Patient for which the decision to initiate treatment with ofatumumab was made by the doctor (investigator) in accordance with his/her usual practices independently of the study
• • 5. Patient not opposed to participation in this study
• • 6. Patient willing and able to complete patient questionnaires
• Exclusion Criteria:
• • 1. Patient treated with ofatumumab in the context of a clinical trial